Background
==========

In Romania, the incidence of hepatocellular carcinoma (HCC) has increased over the past ten years due to the increasing number of cirrhotic patients (more than 90% of the cases of HCC develop in cirrhosis). Antiviral nucleos(t)ide analogues have been widely used to reduce the development of HCC in chronic hepatitis B patients with fibrosis or cirrhosis.

Methods
=======

We included 36 patients with hepatitis B virus related cirrhosis. Since February 2008 until now, 45% (16 patients) were treated with lamivudine and 55% (20 patients) with entecavir. The evaluation was performed every 3-4 months by clinical exam, biochemical and serological tests, and abdominal ultrasonography for all patients. Upper endoscopy, computed tomography scanning or magnetic resonance imaging were done in selective cases.

Results
=======

The median age at the diagnosis of cirrhosis was 57.6±10.7 years and 75% of patients were males. Six cases (16.66%) were diagnosed with HCC -- all of them were males. Only one of these patients was treated with entecavir, while the rest received lamivudine. Risk factors involved in carcinogenesis were represented by: age over 60, male gender, cirrhosis evolution for more than 5 years.

Conclusion
==========

The results of this study suggested that the incidence of HCC is lower in patients with HBV-related cirrhosis who used entecavir (5%) compared to lamivudine (31%).
